Essential thrombocythemia after allogeneic bone marrow transplantation for chronic myelogenous leukemia

Bone Marrow Transplant. 1998 Jul;22(1):107-9. doi: 10.1038/sj.bmt.1701292.

Abstract

Allogeneic transplant recipients are at high risk of developing secondary malignancies as a late complication of therapy. We report a case of essential thrombocythemia occurring 8 years following bone marrow transplantation (BMT) for chronic myelogenous leukemia.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bone Marrow Transplantation / adverse effects*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Thrombocytosis / etiology*
  • Transplantation Chimera
  • Transplantation, Homologous